C5a Specific Neutra™ Antibody Products

Are drug development delays or inefficient inflammatory disease targeting impeding your progress? Creative Biolabs' C5a specific Neutra™ antibody products empower precision-driven outcomes with engineered high-affinity antibodies validated for functional neutralization and therapeutic efficacy.

Introduction to C5a

The complement component 5 alpha chain (C5a) is a critical anaphylatoxin derived from proteolytic cleavage of C5 during complement system activation. As a potent mediator of innate immunity, C5a orchestrates inflammatory responses, chemotaxis, and cellular activation through interactions with its cognate receptor, C5aR1 (CD88). Dysregulation of C5a signaling underlies numerous pathological conditions, making it a high-value therapeutic target.

• Structural Insights

C5a is a 74-amino acid glycoprotein characterized by a compact tertiary structure stabilized by three disulfide bonds. Its N-terminal helical domain mediates receptor binding, while the C-terminal region drives effector functions. Upon complement activation, C5 undergoes cleavage by convertases (e.g., C5 convertase in the classical/alternative pathways) to generate C5a and C5b, the latter initiating membrane attack complex (MAC) assembly.

• C5a Signaling Pathways

C5a exerts biological effects primarily via binding to C5aR1, a G protein-coupled receptor expressed on neutrophils, macrophages, and endothelial cells. This interaction triggers intracellular signaling cascades, including:

1. NF-κB activation, amplifying pro-inflammatory cytokine production (e.g., IL-6, TNF-α).

2. MAPK pathway stimulation, promoting leukocyte chemotaxis and oxidative burst.

3. PI3K/Akt modulation, enhancing cell survival and tissue infiltration.

• Pathological Relevance

Excessive C5a generation is implicated in inflammatory and autoimmune disorders. Key associations include:

- Sepsis: C5a overproduction exacerbates cytokine storms, contributing to multi-organ failure.

- Rheumatoid Arthritis: Synovial fluid C5a levels correlate with joint destruction and neutrophil activation.

- Ischemia-Reperfusion Injury: C5a-mediated inflammation aggravates post-ischemic tissue damage in cardiac and renal systems.

Fig.1 C5a in rheumatoid arthritis.¹

Applications of C5a Neutralizing Antibodies

• Therapeutic Intervention in Inflammatory Diseases

Anti-C5a antibodies mitigate hyperinflammatory responses in sepsis by attenuating systemic cytokine release. In rheumatoid arthritis, they reduce neutrophil infiltration and cartilage degradation, offering a targeted alternative to broad immunosuppressants.

• Organ Protection in Ischemia-Reperfusion Injury

By inhibiting C5a-driven neutrophil activation, these antibodies minimize oxidative damage in reperfused tissues. Clinical trials in myocardial infarction models show improved cardiac function and reduced infarct size.

• Infection Control and Immune Modulation

In bacterial infections, C5a neutralization limits excessive inflammation without compromising bacterial clearance. This dual action preserves host defense mechanisms while preventing sepsis-related complications.

Our Anti-C5a Neutralizing Antibodies

Creative Biolabs' Anti-C5a antibodies are meticulously engineered to block C5a-C5aR1 interactions with exceptional specificity. These antibodies exhibit:

- High affinity (sub-nanomolar KD) for both human and murine C5a, enabling cross-species translational studies.

- Robust neutralization in in vitro models of leukocyte migration and cytokine release.

- Validated performance in ELISA, flow cytometry, and immunohistochemistry (IHC), ensuring reproducibility across experimental platforms. Preclinical studies demonstrate their efficacy in reducing pathological inflammation in sepsis and autoimmune models, highlighting their therapeutic potential.

Creative Biolabs' C5a specific Neutra™ antibody products are indispensable tools for researchers tackling inflammation-driven pathologies. With rigorously validated specificity and therapeutic efficacy, these antibodies accelerate drug discovery and preclinical development.

Contact our team to explore customized solutions for your C5a-related projects.

REFERENCE

1. Ruocco, Anna, et al. "The role of C5a-C5aR1 axis in bone pathophysiology: A mini-review." Frontiers in Cell and Developmental Biology 10 (2022): 957800. Distributed under Open Access license CC BY 4.0, without modification. https://doi.org/10.3389/fcell.2022.957800